article thumbnail

Semaglutide and BP, HF Risk Assessment Using Biomarkers, DAPT After Drug-Eluting Stenting in ACS

American College of Cardiology

In this week’s View, Dr. Eagle looks at an individual patient data meta-analysis of semaglutide and blood pressure (BP). He then explores an analysis from COMBINE-AF on heart failure (HF) risk assessment using biomarkers in patients with atrial fibrillation.

article thumbnail

Comparison of Ambulatory and Home Blood Pressure Variability for Cardiovascular Prognosis and Biomarkers

Hypertension Journal

BPV was evaluated by the SD, coefficient of variation, and average real variability of the patients’ 24-hour ambulatory and home systolic BP values.RESULTS:During the median 7.0-year year follow-up, 109 cardiovascular events occurred.

article thumbnail

Associations of Proteomics With Hypertension and Systolic Blood Pressure: KORA S4/F4/FF4 and KORA-Age1/Age2 Cohort Studies

Hypertension Journal

BACKGROUND:Hypertension, a complex condition, is primarily defined based on blood pressure readings without involving its pathophysiological mechanisms. Generalized estimating equations were used to estimate the associations of 233 plasma proteins with hypertension and systolic blood pressure (SBP). years of follow-up.

article thumbnail

Obesity-Related Biomarkers Are Associated With Exercise Intolerance and HFpEF

Circulation: Heart Failure

Fasting blood samples collected at the time of the cardiopulmonary exercise test were used to assay obesity-related biomarkers. Our findings suggest that among the obesity-related biomarkers studied, higher levels of leptin and CRP are independently associated with increased odds of HFpEF, with odds ratios of 1.36 (95% CI, 1.09–1.70)

article thumbnail

Investigators identify novel plasma proteins linked to future risk of hypertension

Medical Xpress - Cardiology

For example, blood pressure changes during exercise (EBP) can reveal a latent tendency toward future development of hypertension. At present, there is no reliable circulating biomarker—a protein or other molecule present in the blood stream—indicative of hypertension risk.

article thumbnail

Risk factors and prediction model for new-onset hypertensive disorders of pregnancy: a retrospective cohort study

Frontiers in Cardiovascular Medicine

We collected maternal clinical parameters and biomarkers between 16th and 20th weeks of gestation. The HDP group exhibited significantly higher baseline body mass index (BMI), weight change, baseline systolic/diastolic blood pressure, and platelet counts than the control group. 1.17), 1.10 (1.05–1.16), 1.16), 1.04 (1.01–1.08),

article thumbnail

5 Most-Cited Takeaways From the 19th Annual Cardiometabolic Health Congress (CMHC) 

Cardiometabolic Health Congress

He emphasized the evolving landscape of biomarker utility in enhancing the accuracy of HF prediction and the need for targeted interventions based on these biomarkers. He emphasized the evolving landscape of biomarker utility in enhancing the accuracy of HF prediction and the need for targeted interventions based on these biomarkers.

CME 96